Non-fucosylated Anti-Human TNFSF12 (Enavatuzumab) Therapeutic Antibody (CAT#: BioBet-478ZP) Datasheet

TNFSF12

TNFSF12 Gene(Protein Coding)


TNF Superfamily Member 12

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is a ligand for the FN14/TWEAKR receptor. This cytokine has overlapping signaling functions with TNF, but displays a much wider tissue distribution. This cytokine, which exists in both membrane-bound and secreted forms, can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. This cytokine is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Alternative splicing results in multiple transcript variants. Some transcripts skip the last exon of this gene and continue into the second exon of the neighboring TNFSF13 gene; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. [provided by RefSeq, Oct 2010]

Enavatuzumab; 912628-39-8; PDL192; TNFSF12; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor ligand superfamily member 12; APO3L; DR3LG; TWEAK; APO3 ligand; APO3/DR3 ligand; TNF-related WEAK inducer of apoptosis; MGC20669; MGC129581;

Plasma membrane, Extracellular region or secreted

Diseases associated with TNFSF12 include Common Variable Immunodeficiency and Amnestic Disorder.

Its related pathways are Apoptosis Modulation and Signaling and PEDF Induced Signaling.

It binds to FN14 and may also bind to TNRFSF12/APO3. Weakly induce some types of apoptosis. Mediates the activation of NF-kappa-B. Promote angiogenesis and endothelial cell proliferation. It is also involved in the induction of inflammatory cytokines. Promote IL8 secretion.

1.The soluble form derives from the membrane form by proteolytic processing. 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn139

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1, κ

Enavatuzumab

Humanized and chimeric

Human

ADCC-enhanced Enavatuzumab is a non-fucosylated anti-TNFSF12 therapeutic biobetter antibody.

Solid tumors

Solid tumors